Pfizer is licensing around 100 of its small molecule compounds to Bristol, UK-based Tocris Bioscience and St Louis, US-based Sigma-Aldrich. Under the agreements, unformulated patented and approved drug molecules such as atorvastatin, sildenafil and sunitinib will be sold for use in pre-clinical research studies. In addition, a number of Pfizer’s literature compounds that have not progressed from development to clinical use will also be offered for sale.
Laurence Ede, Tocris’s managing director, told Chemistry World that the announcement continued the considerable momentum that the company had seen throughout 2009 despite the widespread economic doom and gloom. That momentum saw the company’s sales increase 17 per cent compared to 2008, with sales of new products introduced in 2009 surpassing even 2008’s record levels.
‘This license is a forward looking move that, as well as being a welcome additional boost to our product range, is a great endorsement of our company by Pfizer - it should also help us maintain the growth that we achieved in 2009 through 2010 and beyond,’ said Ede.